Therakind enters exclusive distribution partnership with Oresund Pharma

Therakind Ltd, a London based specialty pharmaceutical company, has entered into an exclusive distribution partnership with Oresund Pharma ApS, a Danish based specialty pharmaceutical company, for the marketing of Jylamvo in the Nordic countries (Sweden, Finland, Denmark, Iceland, and Norway). Jylamvo has been launched successfully in Norway and Finland and is pending its launch in the remaining Nordic countries.

 Jylamvo is a palatable novel methotrexate 2mg/ml oral solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and for the maintenance treatment of acute lymphoblastic leukaemia (ALL), and for adult psoriasis and psoriatic arthritis.  Jylamvo has a marketing authorization that allows it to be sold throughout the European Economic Area and was the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).

Dr. Susan Conroy, CEO of Therakind, said:

“We are delighted to partner with Oresund and expand the European market for Jylamvo. This product provides benefits and choices for both adults and children suffering from rheumatoid arthritis, JIA, psoriasis, or ALL. We are very pleased about the successful launch of Jylamvo in Norway and Finland and look forward to it being available in other Nordic countries”